- Ixekizumab, a high-affinity monoclonal antibody that selectively targets IL-17A, is efficacious for moderate to severe plaque psoriasis. We examined relationships between serum ixekizumab concentrations, treatment-emergent anti-drug antibodies (TE-ADAs), and efficacy during 60 weeks of treatment in a randomized, controlled, phase 3 study. Steady-state ixekizumab serum trough concentrations were rapidly achieved and associated with high clinical responses at week 12 with a starting dose of 160 mg followed by 80 mg every 2 weeks.
- We would like to provide additional context regarding interpretation of the recently published paper by Jabbar-Lopez et al. (2017). This report performed a systematic review of the literature and network meta-analysis (NMA) to compare six biologics licensed for the treatment of psoriasis with each other, methotrexate, or placebo in an attempt to inform patient and clinician decisions as well as to update the British Association of Dermatologists’ guidelines regarding prioritizations of biologic therapies in psoriasis.